Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Combining MRD quantitation and genetics in post-remission risk stratification

ALL Assembly 2018

Published: 18 Oct 2018

Views: 2092

Rating:

Save

Dr John Moppett - University Hospitals Bristol NHS Foundation Trust, Bristol, UK

Dr John Moppett talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about how to combine MRD quantitation and genetics in post-remission risk stratification.

Dr Moppett discusses the different markers for ALL with emphasis on minimal residual disease (MRD).

He also explains the complexity behind explaining the prognosis to patients due to it's own complex nature.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related Videos

IRANCANSURV: Dissecting the variances in childhood cancer survival across Iran

Dr Saeed Nemati - International Agency for Research on Cancer , Lyon, France

IRANCANSURV: Dissecting the variances in childhood cancer survival across Iran ( Dr Saeed Nemati - International Agency for Research on Cancer , Lyon, France )

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM

Dr Jill Corre - IUCT Oncopole, Toulouse, France

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Revolutionising myeloma treatment through immune profiling

Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA

Revolutionising myeloma treatment through immune profiling ( Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA )

Guiding transplant decisions in multiple myeloma with MRD

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Guiding transplant decisions in multiple myeloma with MRD ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

Revolutionising multiple myeloma treatment with CAR T-Cell therapies

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Revolutionising multiple myeloma treatment with CAR T-Cell therapies ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini

ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )

Status of anti BCMA therapy in myeloma

Dr Dibakar Podder - Tata Medical Center, Kolkata, India

Status of anti BCMA therapy in myeloma ( Dr Dibakar Podder - Tata Medical Center, Kolkata, India )

A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece

A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )

More from ecancer